Purpose: The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.
From the blog
Your Asbestosis Could Lead to Lung Cancer or Mesothelioma
Asbestosis, while not a cancerous condition, is serious and potentially life-threatening chronic disease that is caused by breathing in asbestos fibers. A person who has been diagnosed with asbestosis has a much higher chance of developing lung cancer or pleural mesothelioma, a fatal cancer affecting the lining of the lungs.[…]
Call Your State Senators to Oppose the Furthering Asbestos Claims Transparency Act
A new bill was approved by the U.S. House Judiciary Committee that could damage the asbestos claims process and prevent victims of asbestos-related diseases from ever seeing any sort of monetary compensation before they pass. The legislation is “H.R. 906” and is referred to as the “Furthering Asbestos Claims Transparency[…]
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Purpose The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with nivolumab in participants with locally advanced or metastatic solid tumors. The study will consist of 2 parts: ABBV-368 dose escalation and ABBV-368 tumor-specific dose expansion (non-small cell lung cancer [NSCLC] cohort and head and neck cancer cohort) .
Nutritional Status and Tumor Thickness Helps Determine Mesothelioma Prognosis
The overall nutritional health of a patient suffering from mesothelioma can have major impact on how the patient will respond to treatment, which affects patient survival. To determine a patient’s nutritional factors on a more exact basis, researchers and scientists from Japan used a scoring system called Controlling Nutritional Status[…]
Atezolizumab and Bevacizumab in Rare Solid Tumors
Purpose: The goal of this clinical research study is to learn if atezolizumab and bevacizumab can help to control rare solid tumors.
Despite Asbestos Regulations, CDC Reports Increase in Mesothelioma
Mesothelioma is a type of cancer that is specifically caused by asbestos exposure. The cancer affects the lining surrounding various organs and cavities within the body called the mesothelium. Asbestos fibers, which are nearly invisible, sharp, and easily inhaled, become embedded in this soft tissue. The body is unable to[…]
Partial Repeal in the ACA Preserves Provisions for Residents in Libby, Montana
The dangers of asbestos have affected thousands of residents in the small town of Libby, Montana for decades. In 1919, the town that was once known for its logging industry discovered vermiculite mines – a naturally occurring mineral that is useful for fire-proofing, wall and loft insulation, and even soil[…]
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Purpose: The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986148 administered alone and in combination with nivolumab in patients with mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer and gastric cancer.
Immunotherapy Drug Tremelimumab Not As Effective As Hoped
Mesothelioma’s aggressive nature makes it difficult to treat with common cancer treatments such as chemotherapy and radiation. Scientists and researchers are constantly looking for new ways to treat mesothelioma outside of chemotherapy and radiation, such as gene therapy or immunotherapy. Immunotherapy is a novel approach and sometimes a more viable[…]
Skip to content